uh, well, a programme tomorrow, a big programme with some very important guests and also practising for the election. so for most of the day i will be locked in the basement in broadcasting house. so, if this is recorded, does that mean it ll be better than the last three weeks that we ve done? we can only hope. i wonder if they ve taken that bit out. anyway, this is getting too meta now, so, i actually wonder how many hours it is until the polls close. well, we don t know because we don t know what time it is because we re in the wrong time. oh, this is getting very confusing. shall we get on with it? yeah, yeah. laura, what are your predictions, then, for the last few days of campaigning? well, ithink, look, it s been a very, very eventful campaign. so, you know, 2a hours ago, nobody would have predicted that the prime minister would have inserted himself very dramatically into a race row about reform candidates. so i m not going to make predictions about specifics. however
Synthetic Oligonucleotides: Regulatory, Analytical & Manufacturing Considerations
By Maura Kibbey, Ph.D., and Nick Healy, U.S. Pharmacopeia (USP)
After decades of investment, research, and development, the therapeutic value of oligonucleotides has started to materialize. Dozens of developers now have dedicated pipelines for diverse indications such as oncology, central nervous system diseases, cardiometabolic disorders, liver diseases, and viral infections, including COVID-19. A search for “oligonucleotide” on ClinicalTrials.gov returned more than 50 active studies. Advances in analytical methods are helping to support these pipelines.
Across the development and release landscapes, methods continue to refine, streamline, and support the development of oligonucleotides from new applications of nuclear magnetic resonance (NMR) spectroscopy that are pushing the boundaries of what can be accomplished in development, to innovative platform approaches for specification and release t